Amniotics AB Completes Phase Ib Study of PulmoStem
The study results will be integrated into the further development of PulmoStem in fibrotic and inflammatory lung diseases.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0037 SEK | +2.78% | -5.13% | -58.89% |
1st Jan change | Capi. | |
---|---|---|
-58.89% | 927K | |
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |